Article Versions Notes

Słowińska-Klencka D, Popowicz B, Kulczycka-Wojdala D, Szymańska B, Duda-Szymańska J, Wojtaszek-Nowicka M, Kaczka K, Klencki M. Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia. Cancers. 2023; 15(17):4287. https://doi.org/10.3390/cancers15174287

Słowińska-Klencka, Dorota, Bożena Popowicz, Dominika Kulczycka-Wojdala, Bożena Szymańska, Joanna Duda-Szymańska, Martyna Wojtaszek-Nowicka, Krzysztof Kaczka, and Mariusz Klencki. 2023. "Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia" Cancers 15, no. 17: 4287. https://doi.org/10.3390/cancers15174287

Słowińska-Klencka, D., Popowicz, B., Kulczycka-Wojdala, D., Szymańska, B., Duda-Szymańska, J., Wojtaszek-Nowicka, M., Kaczka, K., & Klencki, M. (2023). Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia. Cancers, 15(17), 4287. https://doi.org/10.3390/cancers15174287